Lyell Immunopharma, Inc. Common Stock

LYELNASDAQ • USD
13.64 USD
↘ 1.02 (6.96%)🟢LIVE (AS OF 11:54 AM EST)
🟢Market: OPEN

Lyell Immunopharma, Inc. Common Stock (LYEL) is currently trading at $13.64. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics place LYEL at a fair price relative to peers.

Technical & fundamental data as of Nov 16, 2026.

Open?$14.58
High?$15.02
Low?$13.29
Prev. Close?$14.65
Volume?64.8K
Avg. Volume?227.8K
VWAP?$13.82
Rel. Volume?0.28x
Bid / Ask
Bid?$11.63 × 100
Ask?$15.51 × 100
Spread?$3.88
Midpoint?$13.57
Valuation & Ratios
Market Cap?469.0M
Shares Out?24.6M
Float?8.8M
Float %?36.1%
P/E Ratio?N/A
P/B Ratio?2.43
EPS?-$7.97
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Employees
161
Market Cap
351.6M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2021-06-17
Address
201 HASKINS WAY
SOUTH SAN FRANCISCO, CA 94080
Phone: 650 695-0677
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
17
Short Sent.?
19
Piotroski F-Score?0/9Weak
Altman Z-Score?-8.03Distress
Confidence?74%Moderate
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?15.95%High
Short Interest?1.4M
Days to Cover?10.4
Free Float8.8M
Avg Daily Volume135.2K
Settlement Date2026-10-30
Financial Health
Current Ratio?4.02Strong
Quick Ratio?4.02Strong
Cash Ratio?1.99Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
66
2.43CHEAP▾
P/S?
Peers
100
S&P
3
31,268.68HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.9CHEAP▾
EV/Sales?
Peers
100
S&P
3
25,131.81HIGH▾
Returns & Efficiency
ROE?
S&P
3
-132.4%WEAK▾
ROA?
S&P
3
-93.2%WEAK▾
Cash Flow & Enterprise
FCF?$-139965000
Enterprise Value?$377.0M
Fundamentals ratios updated end of day